Assessing the feasibility and external validity of natural language processing-extracted data for advanced lung cancer patients.

Journal: Lung cancer (Amsterdam, Netherlands)
PMID:

Abstract

BACKGROUND: Manual extraction of real-world clinical data for research can be time-consuming and prone to error. We assessed the feasibility of using natural language processing (NLP), an AI technique, to automate data extraction for patients with advanced lung cancer (aLC). We assessed the external validity of our NLP-extracted data by comparing our findings to those reported in the literature.

Authors

  • Yuchen Li
    Department of Medical Oncology, Shanghai Key Laboratory of Medical Epigenetics, Fudan University Shanghai Cancer Center, Institutes of Biomedical Sciences, Fudan University, 270 Dong An Rd, Shanghai, 200032, China.
  • Jennifer Law
    Department of Medical Oncology, Princess Margaret Cancer Centre, University Health Network, Toronto, ON M5G 2C1, Canada.
  • Lisa W Le
    Dept. of Biostatistics, University Health Network, Toronto, ON, Canada.
  • Janice J N Li
    Dept. of Medical Oncology, Princess Margaret Cancer Center, Toronto, ON, Canada.
  • Christopher Pettengell
    Pentavere, 460 College Street, Toronto, ON M6G 1A1, Canada.
  • Patricia Demarco
    Hoffman-La Roche Limited (Roche Canada), Mississauga, ON, Canada.
  • Michael Duong
    Hoffman-La Roche Limited (Roche Canada), Mississauga, ON, Canada.
  • David Merritt
    Hoffman-La Roche Limited (Roche Canada), Mississauga, ON, Canada.
  • Sean Davidson
    TECHNA Institute, Toronto, ON, Canada.
  • Mike Sung
    Dept. of Medical Oncology, Princess Margaret Cancer Center, Toronto, ON, Canada.
  • Qixuan Li
    Department of Radiotherapy Oncology, Changzhou No.2 People's Hospital, Nanjing Medical University, Changzhou, China.
  • Sally Cm Lau
    Dept. of Medical Oncology, Princess Margaret Cancer Center, Toronto, ON, Canada.
  • Sajda Zahir
    Dept. of Medical Oncology, Princess Margaret Cancer Center, Toronto, ON, Canada.
  • Ryan Chu
    Georgia Institute of Technology, Atlanta, GA, USA.
  • Malcom Ryan
    Dept. of Medical Oncology, Princess Margaret Cancer Center, Toronto, ON, Canada.
  • Khizar Karim
    Dept. of Medical Oncology, Princess Margaret Cancer Center, Toronto, ON, Canada.
  • Josh Morganstein
    Dept. of Medical Oncology, Princess Margaret Cancer Center, Toronto, ON, Canada.
  • Adrian Sacher
    Department of Medical Oncology, Princess Margaret Cancer Centre, University Health Network, Toronto, ON M5G 2C1, Canada.
  • Lawson Eng
    Princess Margaret Cancer Centre, University Health Network, Temerty Faculty of Medicine, University of Toronto, Toronto, ON, Canada.
  • Frances A Shepherd
    Department of Medical Oncology, Princess Margaret Cancer Centre, University Health Network, Toronto, ON M5G 2C1, Canada.
  • Penelope Bradbury
    Department of Medical Oncology, Princess Margaret Cancer Centre, University Health Network, Toronto, ON M5G 2C1, Canada.
  • Geoffrey Liu
    Medical Oncology and Medical Biophysics, Princess Margaret Cancer Centre, Toronto, Ontario, Canada.
  • Natasha B Leighl
    Department of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada.